News (319)

Ionis Pharmaceuticals : 1Q24 Earnings Slides PU
Transcript : Ionis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
Ionis reports first quarter 2024 financial results PR
Ionis Publishes 2023 Corporate Responsibility Report PR
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
Ionis announces new chief global product strategy officer to lead next phase of commercial growth PR
Transcript : Ionis Pharmaceuticals, Inc., 2023 Earnings Call, Feb 21, 2024
Ionis reports fourth quarter and full year 2023 financial results PR
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema PR
Transcript : Ionis Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases PR
Astrazeneca - Wainua granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis AQ
AstraZeneca : Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis - Form 6-K PU
AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone" AN
WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis BU
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference PR
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema PR
Ionis announces the appointment of Michael Yang to Board of Directors PR
Transcript : Ionis Pharmaceuticals, Inc. Presents at 2023 BMO Growth & ESG Conference, Dec-04-2023
Transcript : Ionis Pharmaceuticals, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-28-2023 10:00 AM
Transcript : Ionis Pharmaceuticals, Inc. Presents at The Stifel 2023 Annual Healthcare Conference, Nov-14-2023 10:55 AM
Transcript : Ionis Pharmaceuticals, Inc. Presents at Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference, Nov-07-2023 11:10 AM
Ionis reports third quarter 2023 financial results AQ
Transcript : Ionis Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization AQ
Ionis Pharmaceuticals : 2023 Ionis Investor Day Presentation PU
Transcript : Ionis Pharmaceuticals, Inc. - Analyst/Investor Day
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome AQ
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease PR
Ionis Pharmaceuticals : Olezarsen Presentation PU
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
Transcript : Ionis Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:15 PM
Transcript : Ionis Pharmaceuticals, Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 01:50 PM
Ionis Pharmaceuticals : 2Q23 Earnings Slides PU
Transcript : Ionis Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Ionis reports second quarter 2023 financial results PR
Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease PR
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America AQ
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America PR
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen’s 2nd Annual RNA Therapeutics Summit, Jul-10-2023 10:25 AM
Transcript : Ionis Pharmaceuticals, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-12-2023 09:20 AM
Ionis Pharmaceuticals : 2023 Virtual Annual Meeting of Stockholders Corporate Update Presentation PU
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
Transcript : Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2023, May-16-2023 10:00 AM
1234NextSee all

Companies (1)

XIMEN MINING CORP. 5 M $
Logo Ximen Mining Corp.

Ximen Mining Corp. is a Canada-based company, which is engaged in the acquisition, exploration, and evaluation of its mineral property interests located in British Columbia. The Company’s Brett Gold Project is situated in the North Okanagan region of so ...


Insiders

Picture Brett Monia
Brett Monia

Founder of Ionis Pharmaceuticals, Inc., Brett P. Monia currently is Chief Executive Officer & Director at this company and President & Director at Akcea Therapeutics, Inc. (a subsidiary of Ionis Pharmaceuticals, Inc.). Dr. Monia is also on the board of Cognition Therapeutics, Inc. and Erie Steel Ltd. and Member of American Diabetes Association, Member of American Association for Cancer Research and Member of American Society of Hematology. In his past career Dr. Monia was President at Oligonucleotide Therapeutics Society, Inc. and Member of American Association for The Study of Liver Diseases. He received a doctorate from the University of Pennsylvania and an undergraduate degree from Stockton University.




Picture Monia Santinello
Monia Santinello

Monia Santinello is the founder of Tinsel, Inc., a company founded in 2015.
She held the title of Vice President-Operations at Tinsel, Inc. from 2015 to 2019.







No results for this search

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW